A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 292, Issue 6, 2007, Pages

  Kariya, Chirag ^a,b   Leitner, Heather ^a,b   Min, Elysia ^a   Van Heeckeren, Christiaan ^c   Van Heeckeren, Anna ^c   Day, Brian J ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Antioxidant; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; High performance liquid chromatography; Mice; Nutrition; Transport

Indexed keywords

GLUTATHIONE; GLUTATHIONE DISULFIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; KNOCKOUT MOUSE; LUNG; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN TRANSPORT; TISSUE LEVEL; TRANSGENIC MOUSE; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE; INTESTINAL ABSORPTION; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CFTR; MICE, KNOCKOUT;

EID: 34447564876     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00365.2006     Document Type: Article

References (57)

1. Accurso FJ. Update in cystic fibrosis 2005. Am J Respir Crit Care Med 173: 944-947, 2006.
2. Aw TY, Wierzbicka G, Jones DP. Oral glutathione increases tissue glutathione in vivo. Chem Biol Interact 80: 89-97, 1991.
3. Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 127: 308-317, 2005.
4. Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, Roum JH, Czerski DB, Cantin AM, Crystal RG. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 338: 215-216, 1991.
5. Bowler RP, Velsor LW, Duda B, Chan ED, Abraham E, Ware LB, Matthay MA, Day BJ. Pulmonary edema fluid antioxidants are depressed in acute lung injury. Crit Care Med 31: 2309-2315, 2003.
6. Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 46: 39-42, 1991.
7. Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 49: 670-675, 1994.
8. Brown RK, Kelly FJ. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res 36: 487-493, 1994.
9. Buhl R, Vogelmeier C, Critenden M, Hubbard RC, Hoyt RF Jr, Wilson EM, Cantin AM, Crystal RG. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc Natl Acad Sci USA 87: 4063-4067, 1990.
10. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 139: 370-372, 1989.
11. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 63: 152-157, 1987.
12. Chinard FP. Quantitative assessment of epithelial lining fluid in the lung. Am J Physiol Lung Cell Mol Physiol 263: L617-L618, 1992.
13. Comhair SA, Lewis MJ, Bhathena PR, Hammel JP, Erzurum SC. Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Am J Respir Crit Care Med 159: 1824-1829, 1999.
14. Dauletbaev N, Viel K, Buhl R, Wagner TO, Bargon J. Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. J Cyst Fibros 3: 119-124, 2004.
15. Day BJ, van Heeckeren AM, Min E, Velsor LW. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary Pseudomonas infection. Infect Immun 72: 2045-2051, 2004.
16. Dominguez C, Gartner S, Linan S, Cobos N, Moreno A. Enhanced oxidative damage in cystic fibrosis patients. Biofactors 8: 149-153, 1998.
17. Droge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc 59: 595-600, 2000.
18. Favilli F, Marraccini P, Iantomasi T, Vincenzini MT. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br J Nutr 78: 293-300, 1997.
19. Fick RB Jr, Sonoda F, and Hornick DB. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway. Semin Respir Infect 7: 168-178, 1992.
20. Gao L, Kim KJ, Yankaskas JR, Forman HJ. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol Lung Cell Mol Physiol 277: L113-L118, 1999.
21. Grey V, Mohammed SR, Smountas AA, Bahlool R, Lands LC. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. J Cyst Fibros 2: 195-198, 2003.
22. Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, Ratjen F, Mullinger B, Huber RM, Maier K, Rietschel E, Scheuch G. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 169: 822-828, 2004.
23. Grimble RF. The effects of sulfur amino acid intake on immune function in humans. J Nutr 136: 1660S-1665S, 2006.
24. Guilbault C, Saeed Z, Downey GP, Radzioch D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36: 1-7, 2007.
25. Gupta S, Rogers LK, Taylor SK, Smith CV. Inhibition of carbamyl phosphate synthetase-I and glutamine synthetase by hepatotoxic doses of acetaminophen in mice. Toxicol Appl Pharmacol 146: 317-327, 1997.
26. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 100: 2810-2815, 1997.
27. Holroyd KJ, Buhl R, Borok Z, Roum JH, Bokser AD, Grimes GJ, Czerski D, Cantin AM, Crystal RG. Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. Thorax 48: 985-989, 1993.
28. Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 30: 1440-1461, 2001.
29. Iwata S, Hori T, Sato N, Ueda-Taniguchi Y, Yamabe T, Nakamura H, Masutani H, Yodoi J. Thiol-mediated redox regulation of lymphocyte proliferation. Possible involvement of adult T cell leukemia-derived factor and glutathione in transferrin receptor expression. J Immunol 152: 5633-5642, 1994.
30. Jaeschke H, Wendel A. Diurnal fluctuation and pharmacological alteration of mouse organ glutathione content. Biochem Pharmacol 34: 1029-1033, 1985.
31. Kelly FJ. Gluthathione: in defence of the lung. Food Chem Toxicol 37: 963-966, 1999.
32. Kogan I, Ramjeesingh M, Li C, Kidd JF, Wang Y, Leslie EM, Cole SP, Bear CE. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 22: 1981-1989, 2003.
33. Lailey AF, Upshall DG. Thiol levels in rat bronchio-alveolar lavage fluid after administration of cysteine esters. Hum Exp Toxicol 13: 776-780, 1994.
34. Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol Cell Physiol 275: C323-C326, 1998.
35. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 121: 654-661, 1993.
36. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest 112: 785-788, 1997.
37. Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 100: 1397-1403, 1991.
38. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol 64: 1027-1035, 2002.
39. Peskin AV, Winterbourn CC. Kinetics of the reactions of hypochlorous acid and amino acid chloramines with thiols, methionine, and ascorbate. Free Radic Biol Med 30: 572-579, 2001.
40. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271: 64-67, 1996.
41. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev 79: S215-S255, 1999.
42. Rahman I, MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol Lung Cell Mol Physiol 277: L1067-L1088, 1999.
43. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 16: 534-554, 2000.
44. Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 87: 438-443, 1999.
45. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 75: 2419-2424, 1993.
46. Slade R, Crissman K, Norwood J, Hatch G. Comparison of antioxidant substances in bronchoalveolar lavage cells and fluid from humans, guinea pigs, and rats. Exp Lung Res 19: 469-484, 1993.
47. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH. An animal model for cystic fibrosis made by gene targeting. Science 257: 1083-1088, 1992.
48. Suntres ZE, Omri A, Shek PN. Pseudomonas aeruginosa-induced lung injury: role of oxidative stress. Microb Pathog 32: 27-34, 2002.
49. van Heeckeren AM, Schluchter M, Xue L, Alvarez J, Freedman S, St George J, Davis PB. Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice. Infect Immun 72: 1479-1486, 2004.
50. Vayalil PK, Olman M, Murphy-Ullrich JE, Postlethwait EM, Liu RM. Glutathione restores collagen degradation in TGF-β-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen. Am J Physiol Lung Cell Mol Physiol 289: L937-L945, 2005.
51. Velsor LW, Kariya C, Kachadourian R, Day BJ. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Respir Cell Mol Biol 35: 579-586, 2006.
52. Velsor LW, van Heeckeren A, Day BJ. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 281: L31-L38, 2001.
53. Wilson GB, Fudenberg HH. Does a primary host defense abnormality involving monocytes-macrophages underlie the pathogenesis of lung disease in cystic fibrosis? Med Hypotheses 8: 527-542, 1982.
54. Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT, Descamps-Latscha B. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit Care Med 152: 1910-1916, 1995.
55. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 43: 667-669, 1992.
56. Yumei F, Zhou Y, Zheng S, Chen A. The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab Invest 86: 697-709, 2006.
57. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266: 1705-1708, 1994.